EA202193281A1 - Новые соединения и их фармацевтические композиции для лечения заболеваний - Google Patents

Новые соединения и их фармацевтические композиции для лечения заболеваний

Info

Publication number
EA202193281A1
EA202193281A1 EA202193281A EA202193281A EA202193281A1 EA 202193281 A1 EA202193281 A1 EA 202193281A1 EA 202193281 A EA202193281 A EA 202193281A EA 202193281 A EA202193281 A EA 202193281A EA 202193281 A1 EA202193281 A1 EA 202193281A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
treatment
compounds
pharmaceutical compositions
new compounds
Prior art date
Application number
EA202193281A
Other languages
English (en)
Inventor
Льюк Джонатан Элви
Дени БЮШЕ
Николя ДЕРУА
Элен Мари Жари
Кристоф Пексото
Тауэ ТЕМАЛЬ-ЛЕБ
Амината ТИРЕРА
Флоранс Мари-Эмили Боннатерр
Беранже ДЮТЬОН
Original Assignee
Галапагос Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галапагос Нв filed Critical Галапагос Нв
Publication of EA202193281A1 publication Critical patent/EA202193281A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В настоящем изобретении раскрыты соединения, соответствующие формуле Iгде R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y и Z определены в изобретении. Настоящее изобретение относится к соединениям, способам их получения, фармацевтическим композициям, включающим эти соединения, и способам лечения, использующим эти соединения, для профилактики или лечения воспалительных заболеваний, аутовоспалительных заболеваний, аутоиммунных заболеваний, пролиферативных заболеваний, фиброзных заболеваний, отторжения при трансплантации, заболеваний, связанных с нарушением обновления хряща, врожденного дефекта хряща, заболеваний, связанных с нарушением ремоделирования кости, заболеваний, связанных с гиперсекрецией IL-6, заболеваний, связанных с гиперсекрецией TNF, интерферонов, IL-12 и/или IL-23, респираторных заболеваний, эндокринных и/или метаболических заболеваний, сердечно-сосудистых заболеваний, дерматологических заболеваний и/или заболеваний, связанных с аномальным ангиогенезом, путем введения соединения по изобретению.
EA202193281A 2019-05-29 2020-05-25 Новые соединения и их фармацевтические композиции для лечения заболеваний EA202193281A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1907616.5A GB201907616D0 (en) 2019-05-29 2019-05-29 Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
PCT/EP2020/064368 WO2020239658A1 (en) 2019-05-29 2020-05-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
EA202193281A1 true EA202193281A1 (ru) 2022-03-01

Family

ID=67385363

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193281A EA202193281A1 (ru) 2019-05-29 2020-05-25 Новые соединения и их фармацевтические композиции для лечения заболеваний

Country Status (22)

Country Link
US (1) US20220340548A1 (ru)
EP (1) EP3976189B1 (ru)
JP (1) JP7550174B2 (ru)
KR (1) KR20220015450A (ru)
CN (1) CN113924146A (ru)
AR (1) AR119028A1 (ru)
AU (1) AU2020281650A1 (ru)
BR (1) BR112021023900A2 (ru)
CA (1) CA3141683A1 (ru)
CL (1) CL2021003133A1 (ru)
CO (1) CO2021017656A2 (ru)
CR (1) CR20210586A (ru)
EA (1) EA202193281A1 (ru)
GB (1) GB201907616D0 (ru)
IL (1) IL288375A (ru)
MA (1) MA56019A (ru)
MX (1) MX2021013803A (ru)
PE (1) PE20220503A1 (ru)
PL (1) PL3976189T3 (ru)
SG (1) SG11202112652RA (ru)
TW (1) TW202110839A (ru)
WO (1) WO2020239658A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312955A (en) 2019-03-11 2024-07-01 Inflarx Gmbh Fused Piperidinyl Bicyclic Compounds and Related Compounds as C5A Receptor Modulators
USD982434S1 (en) * 2021-08-31 2023-04-04 Level Up Dice LLC Dice storage container
CN118119619A (zh) * 2021-10-18 2024-05-31 上海美悦生物科技发展有限公司 Sik抑制剂及其组合物、制备方法和用途
AR128279A1 (es) * 2022-01-19 2024-04-10 Hoffmann La Roche Nuevos derivados de bencimidazol piridina
CN115304605B (zh) * 2022-01-21 2023-10-03 陕西国际商贸学院 具有抗肿瘤活性的氧杂环丁烷衍生物及其制备方法和应用
WO2024003209A1 (en) * 2022-07-01 2024-01-04 F. Hoffmann-La Roche Ag Imidazo[4,5-c]pyridine derivatives as sik modulators for the treatment of rheumatoid arthritis
WO2024104441A1 (en) * 2022-11-17 2024-05-23 Insilico Medicine Ip Limited Salt-inducible kinases (sik) inhibitors and methods of uses thereof
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178375B1 (en) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazoloý1,5-a¨pyrimidine derivatives
CN103282034A (zh) * 2010-11-18 2013-09-04 利亘制药公司 造血生长因子模拟物的用途
EP2646215A1 (en) 2010-12-01 2013-10-09 Plasan Carbon Composites, Inc. Method and system for forming composite articles
US9512126B2 (en) * 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
WO2017040993A1 (en) 2015-09-03 2017-03-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1a and uses thereof
CN106496222A (zh) 2016-09-07 2017-03-15 华东师范大学 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用
WO2019105886A1 (en) * 2017-12-02 2019-06-06 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
CN108358894B (zh) * 2018-04-26 2021-05-07 四川大学 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用
MX2020013275A (es) 2018-06-15 2021-02-18 Galapagos Nv Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.

Also Published As

Publication number Publication date
MA56019A (fr) 2022-04-06
TW202110839A (zh) 2021-03-16
EP3976189B1 (en) 2024-07-03
EP3976189A1 (en) 2022-04-06
MX2021013803A (es) 2021-12-14
CL2021003133A1 (es) 2022-07-22
US20220340548A1 (en) 2022-10-27
CA3141683A1 (en) 2020-12-03
PL3976189T3 (pl) 2024-09-09
CR20210586A (es) 2022-01-24
IL288375A (en) 2022-01-01
JP2022534578A (ja) 2022-08-02
GB201907616D0 (en) 2019-07-10
CN113924146A (zh) 2022-01-11
AU2020281650A1 (en) 2022-02-03
WO2020239658A1 (en) 2020-12-03
EP3976189C0 (en) 2024-07-03
KR20220015450A (ko) 2022-02-08
PE20220503A1 (es) 2022-04-07
SG11202112652RA (en) 2021-12-30
JP7550174B2 (ja) 2024-09-12
AR119028A1 (es) 2021-11-17
BR112021023900A2 (pt) 2022-01-18
CO2021017656A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
EA202193281A1 (ru) Новые соединения и их фармацевтические композиции для лечения заболеваний
MX2020005423A (es) Nuevos compuestos y sus composiciones farmaceuticas para el tratamiento de enfermedades.
PH12020552160A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
MX2020003863A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
EA201590071A1 (ru) Аминотриазолопиридин для применения в лечении воспаления и его фармацевтические композиции
CR20200578A (es) Análogos de rapamicina a c40, c28 y c32 como inhibidores de mtor
EA202091512A1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
EA201270076A1 (ru) Новое соединение, применимое для лечения дегенеративных и воспалительных заболеваний
MX2013012281A (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
MX2019015350A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de la fibrosis.
TW201613873A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL287523A (en) Useful preparations for the treatment of Pompe disease
MX2021014157A (es) Formas cristalinas de un inhibidor btk.
BR112018075415A2 (pt) composição mastigável macia compreendendo plantago
EA201992152A1 (ru) Химические соединения
GB201904373D0 (en) Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
PH12019501853A1 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
MX2021011575A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2022004565A (es) Tienopirimidonas como inhibidores de trpa1.